Mounjaro and Ozempic are both weekly injectable medications used to manage type 2 diabetes, but they contain different active ingredients, work through different biological pathways, and produce notably different results for weight loss and blood sugar control. Mounjaro (tirzepatide), made by Eli Lilly, targets two gut hormones simultaneously, while Ozempic (semaglutide), made by Novo Nordisk, targets one. That distinction drives most of the practical differences between them.
How They Work in the Body
Ozempic mimics a single gut hormone called GLP-1, which your body naturally releases after eating. This hormone signals your pancreas to produce more insulin, slows digestion, and reduces appetite. Mounjaro does the same thing but also mimics a second gut hormone called GIP. This dual action appears to amplify the effects on both blood sugar and body weight, which is why Mounjaro consistently outperforms Ozempic in head-to-head trials.
FDA-Approved Uses
Both medications are approved for managing blood sugar in adults with type 2 diabetes. Neither is officially approved as a standalone weight loss drug under its diabetes brand name. However, tirzepatide (Mounjaro’s active ingredient) is also sold under the brand name Zepbound, which is specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Similarly, semaglutide (Ozempic’s active ingredient) is sold as Wegovy for weight management. Doctors frequently prescribe both Mounjaro and Ozempic off-label for weight loss, but the dedicated weight loss versions carry different dosing and labeling.
Weight Loss Comparison
This is where the gap between the two drugs is most striking. In diabetes trials, patients on Ozempic typically lose 6% to 7% of their body weight. Patients on Mounjaro lose significantly more, averaging between 12 and 25 pounds depending on dose, even though weight loss isn’t its primary indication.
When tirzepatide was studied specifically for weight loss in people without diabetes (the SURMOUNT-1 trial), the results were dramatic. At the highest dose, participants lost an average of 48 pounds, or about 21% of their body weight, over 72 weeks. Even the lowest dose produced an average loss of 34 pounds, or 15% of body weight. In a direct head-to-head trial (SURMOUNT-5), tirzepatide delivered 47% greater weight loss compared to semaglutide: an average reduction of 20.2% versus 13.7%.
For people with type 2 diabetes, weight loss is harder to achieve with any medication. Even so, tirzepatide produced 12.8% to 14.7% body weight loss in that population, well above what semaglutide delivers.
Blood Sugar Control
Mounjaro also has an edge for lowering A1C, the measure of average blood sugar over roughly three months. In the SURPASS-2 trial, which directly compared the two drugs in patients starting from an average A1C of 8.3%, Mounjaro reduced A1C by 2.0% to 2.3% depending on dose. Ozempic at its 1 mg dose reduced A1C by 1.9%. The difference is modest at lower Mounjaro doses but becomes more meaningful at 10 mg and 15 mg.
Dosing and Titration Schedule
Both drugs start at a low dose and gradually increase over several weeks to reduce side effects. Mounjaro begins at 2.5 mg weekly, stepping up to 5 mg after four weeks. From there, your doctor can increase the dose in increments up to a maximum of 15 mg weekly, with at least four weeks between each increase.
Ozempic starts even lower at 0.25 mg weekly, moving to 0.5 mg after four weeks. If more blood sugar control is needed, the dose can eventually reach a maximum of 2 mg weekly. The slower ramp-up means it can take longer to reach a maintenance dose with Ozempic, though some patients do well at lower doses and never need the maximum.
Side Effects
Gastrointestinal problems are the most common side effects of both medications, and this is one area where Mounjaro may actually have an advantage. Based on patient-reported data, nausea affects about 17% of Mounjaro users compared to 33% of Ozempic users. Diarrhea occurs in roughly 9% of Mounjaro users versus 17% of Ozempic users. Vomiting is reported by about 5% on Mounjaro compared to 12% on Ozempic.
These side effects tend to be worst during dose increases and often improve as your body adjusts. The gradual titration schedule for both drugs exists specifically to minimize these issues. Eating smaller meals, avoiding high-fat foods, and staying hydrated can also help.
Heart Health
Semaglutide has established cardiovascular benefits, with prior trials showing it reduces the risk of major cardiac events in people with type 2 diabetes and heart disease. Tirzepatide’s cardiovascular data is newer. In the SURPASS-CVOT trial, Mounjaro reduced all-cause mortality by 16% compared to another diabetes drug (dulaglutide). A further analysis estimated that Mounjaro reduced the risk of heart attack, stroke, or cardiovascular death by 28% and all-cause mortality by 39% compared to placebo.
How You Take Them
Both are once-weekly injections given under the skin, typically in the thigh, abdomen, or upper arm. Mounjaro comes in single-dose prefilled pens, meaning each pen is used once and discarded. Ozempic uses a multi-dose pen that lasts for multiple injections, requiring you to attach a new needle each time. Some people prefer the simplicity of Mounjaro’s single-dose design.
Storage is similar for both. Unopened Mounjaro pens should be refrigerated between 36°F and 46°F. Once removed from the fridge, a Mounjaro pen can be kept at room temperature (up to 86°F) for a maximum of 21 days. Neither drug should be frozen.
Cost and Availability
Both medications carry high list prices, typically over $1,000 per month without insurance. Coverage varies widely between insurance plans, and many insurers require prior authorization or evidence that other diabetes treatments haven’t worked. Because Mounjaro is newer, some plans may be slower to add it to their formulary. Manufacturer savings cards and patient assistance programs exist for both, but eligibility depends on your insurance type. Checking with your insurer before filling a prescription can save you from surprises at the pharmacy counter.
Which One Produces Better Results
On the two metrics most patients care about, blood sugar and weight, Mounjaro outperforms Ozempic. It lowers A1C slightly more and produces substantially greater weight loss, while appearing to cause fewer gastrointestinal side effects. That said, Ozempic has a longer track record, more years of real-world safety data, and well-established cardiovascular benefits. Both are effective medications for type 2 diabetes, and the best choice depends on your specific health profile, insurance coverage, and how your body responds to treatment.